Key Points
- Insider sale: Mayukh Sukhatme sold 284,707 Roivant Sciences shares for approximately $10.32 million at an average price of $36.25, reducing his direct stake by 1.51% to 18.63 million shares. He also reported additional sales of 243,177 shares on August 14 and 136,942 shares on August 18.
- Stock and earnings: ROIV opened at $37.37, near its 52-week high of $37.46, with a market capitalization of approximately $26.99 billion. The company reported a quarterly loss of $0.26 per share, better than expectations, but revenue of $1.44 million fell short of estimates.
- Analyst outlook: Roivant has a consensus rating of “Moderate Buy” and an average price target of $35.14, with Guggenheim recently raising its target to $42. Institutional investors and hedge funds own approximately 64.76% of the company.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 136,942 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66. Following the completion of the transaction, the insider owned 18,630,739 shares of the company's stock, valued at $684,307,043.47. The trade was a 0.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Mayukh Sukhatme also recently made the following trade(s):
- On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
- On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.
Roivant Sciences Stock Performance
Shares of NASDAQ ROIV opened at $37.37 on Wednesday. The stock has a 50 day moving average price of $34.16 and a 200 day moving average price of $30.17. Roivant Sciences Ltd. has a 52 week low of $11.54 and a 52 week high of $37.46. The stock has a market capitalization of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. As a group, research analysts forecast that Roivant Sciences Ltd. will post -1.83 EPS for the current year.
Wall Street Analyst Weigh In
ROIV has been the topic of a number of recent analyst reports. Sanford C. Bernstein upgraded shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th. Leerink Partners set a $42.00 price objective on shares of Roivant Sciences in a research report on Thursday, May 21st. Piper Sandler restated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, May 21st. HC Wainwright upped their target price on shares of Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 7th. Finally, Guggenheim raised their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.14.
View Our Latest Analysis on Roivant Sciences
Institutional Investors Weigh In On Roivant Sciences
Large investors have recently added to or reduced their stakes in the business. Fifth Third Bancorp increased its holdings in shares of Roivant Sciences by 8.7% in the first quarter. Fifth Third Bancorp now owns 4,686 shares of the company's stock valued at $130,000 after purchasing an additional 376 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock worth $69,000 after buying an additional 441 shares during the period. Fifth Third Wealth Advisors LLC boosted its holdings in shares of Roivant Sciences by 4.6% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company's stock worth $282,000 after buying an additional 445 shares during the period. Versant Capital Management Inc grew its stake in Roivant Sciences by 13.9% in the 2nd quarter. Versant Capital Management Inc now owns 3,995 shares of the company's stock valued at $141,000 after buying an additional 487 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its stake in Roivant Sciences by 0.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company's stock valued at $1,891,000 after buying an additional 500 shares during the last quarter. Institutional investors own 64.76% of the company's stock.
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
